Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Oliver Ottmann
Long-Term Efficacy and Safety of Dasatinib in Patients With Chronic Myeloid Leukemia in Accelerated Phase Who Are Resistant to or Intolerant of Imatinib
Blood Cancer Journal
Oncology
Hematology
Related publications
Long-Term Safety and Efficacy of Dasatinib in the Treatment of Chronic-Phase Chronic Myeloid Leukemia Patients Resistant or Intolerant to Imatinib
Blood and Lymphatic Cancer: Targets and Therapy
Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Factors Influencing Long-Term Efficacy and Tolerability of Bosutinib in Chronic Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib
British Journal of Haematology
Hematology
Treatment Options for Patients With Chronic Myeloid Leukemia Who Are Resistant to or Unable to Tolerate Imatinib
Clinical Therapeutics
Pharmacology
Dasatinib in the Treatment of Imatinib Refractory Chronic Myeloid Leukemia
Biologics: Targets and Therapy
Oncology
Immunology
Gastroenterology
Pharmacology
Rheumatology
Allergy
A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib in Patients With Chronic Lymphocytic Leukemia (Cll) Who Are Intolerant to Prior BTK or Pi3k Delta Inhibitor Therapy
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib for Patients With Chronic Myeloid Leukemia
Biological and Pharmaceutical Bulletin
Medicine
Pharmacology
Pharmaceutical Science
Multicenter Phase II Clinical Trial of Nilotinib for Patients With Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia From the East Japan CML Study Group Evaluation of Molecular Response and the Efficacy and Safety of Nilotinib
Biomarker Research
Biochemistry
Molecular Medicine
Clinical Biochemistry
Clinical Efficacy and Safety of Imatinib in the Management of Ph+ Chronic Myeloid or Acute Lymphoblastic Leukemia in Chinese Patients
OncoTargets and Therapy
Oncology
Pharmacology
